论文部分内容阅读
目的 探讨甘露扶正口服液配合化疗治疗晚期非小细胞肺癌的临床疗效。方法 将 6 3例肺癌患者随机分为 2组 ,治疗组 33例应用甘露扶正口服液配合化疗治疗 ,对照组 30例采用单纯化疗。观察治疗前后细胞免疫功能与白细胞数测定。结果 治疗组与对照组有效率 (CR +PR)分别为 5 4 .5 %和 37%。临床证候变化 :治疗组与对照组改善率分别为 88%和 5 7% (P <0 .0 1)。中位生存期治疗组 15 .4个月 ,对照组 10 .3个月。细胞免疫功能比较治疗组的CD3 ,CD4,CD4/CD8及NK细胞活性均高于对照组 ,有显著性差异 (P <0 .0 1) ,白细胞计数变化治疗组与对照组比较有显著性差异 (P <0 .0 1)。结论 甘露扶正口服液在晚期非小细胞肺癌化疗过程中可保护骨髓 ,提高机体免疫功能 ,改善生活质量 ,延长生存期。
Objective To investigate the clinical efficacy of Manlu Fuzheng oral solution combined with chemotherapy in the treatment of advanced non-small cell lung cancer. Methods Sixty-three patients with lung cancer were randomly divided into two groups. 33 cases in the treatment group were treated with Ganlu Fusheng oral liquid and chemotherapy, and 30 cases in the control group were treated with chemotherapy alone. Observed before and after treatment of cellular immune function and white blood cell count determination. Results The effective rate (CR + PR) of the treatment group and the control group were 54.5% and 37% respectively. Clinical changes: The improvement rates of the treatment group and the control group were 88% and 57%, respectively (P <0.01). The median survival period was 15.4 months in the treatment group and 10.3 months in the control group. Compared with the control group, the activity of CD3, CD4, CD4 / CD8 and NK cells in the cell-treated group were significantly higher than those in the control group (P <0.01). There was a significant difference between the treatment group and the control group (P <0. 01). Conclusion Manlu Fusheng oral liquid can protect the bone marrow in the chemotherapy of advanced non-small cell lung cancer, improve immune function, improve quality of life and prolong survival.